The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis

A 43-year-old woman, diagnosed with ulcerative colitis (UC) at age of 30, received outpatient treatment with corticosteroids. However, flare-up occurred, and adalimumab (ADA) treatment commenced in July 2009. A complete remission with mucosal healing was achieved by 32 weeks after initiation of ADA...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanida, Satoshi, Mizoshita, Tsutomu, Ozeki, Keiji, Tsukamoto, Hironobu, Mori, Yoshinori, Kubota, Eiji, Kataoka, Hiromi, Kamiya, Takeshi, Joh, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245064/
https://www.ncbi.nlm.nih.gov/pubmed/25436030
http://dx.doi.org/10.14740/jocmr1991w
_version_ 1782346304538542080
author Tanida, Satoshi
Mizoshita, Tsutomu
Ozeki, Keiji
Tsukamoto, Hironobu
Mori, Yoshinori
Kubota, Eiji
Kataoka, Hiromi
Kamiya, Takeshi
Joh, Takashi
author_facet Tanida, Satoshi
Mizoshita, Tsutomu
Ozeki, Keiji
Tsukamoto, Hironobu
Mori, Yoshinori
Kubota, Eiji
Kataoka, Hiromi
Kamiya, Takeshi
Joh, Takashi
author_sort Tanida, Satoshi
collection PubMed
description A 43-year-old woman, diagnosed with ulcerative colitis (UC) at age of 30, received outpatient treatment with corticosteroids. However, flare-up occurred, and adalimumab (ADA) treatment commenced in July 2009. A complete remission with mucosal healing was achieved by 32 weeks after initiation of ADA therapy. Because of progressive skin eruptions, ADA maintenance was discontinued at 124 weeks. Regardless, complete remission with mucosal healing was maintained until 176 weeks. We concluded that ADA is an effective therapy to achieve a complete remission in a patient with steroid-refractory UC, and that long-term complete remission may be an important indication to discontinue biological therapy.
format Online
Article
Text
id pubmed-4245064
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-42450642014-11-28 The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis Tanida, Satoshi Mizoshita, Tsutomu Ozeki, Keiji Tsukamoto, Hironobu Mori, Yoshinori Kubota, Eiji Kataoka, Hiromi Kamiya, Takeshi Joh, Takashi J Clin Med Res Case Report A 43-year-old woman, diagnosed with ulcerative colitis (UC) at age of 30, received outpatient treatment with corticosteroids. However, flare-up occurred, and adalimumab (ADA) treatment commenced in July 2009. A complete remission with mucosal healing was achieved by 32 weeks after initiation of ADA therapy. Because of progressive skin eruptions, ADA maintenance was discontinued at 124 weeks. Regardless, complete remission with mucosal healing was maintained until 176 weeks. We concluded that ADA is an effective therapy to achieve a complete remission in a patient with steroid-refractory UC, and that long-term complete remission may be an important indication to discontinue biological therapy. Elmer Press 2015-02 2014-11-19 /pmc/articles/PMC4245064/ /pubmed/25436030 http://dx.doi.org/10.14740/jocmr1991w Text en Copyright 2015, Tanida et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Tanida, Satoshi
Mizoshita, Tsutomu
Ozeki, Keiji
Tsukamoto, Hironobu
Mori, Yoshinori
Kubota, Eiji
Kataoka, Hiromi
Kamiya, Takeshi
Joh, Takashi
The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
title The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
title_full The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
title_fullStr The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
title_full_unstemmed The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
title_short The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
title_sort first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245064/
https://www.ncbi.nlm.nih.gov/pubmed/25436030
http://dx.doi.org/10.14740/jocmr1991w
work_keys_str_mv AT tanidasatoshi thefirstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT mizoshitatsutomu thefirstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT ozekikeiji thefirstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT tsukamotohironobu thefirstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT moriyoshinori thefirstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT kubotaeiji thefirstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT kataokahiromi thefirstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT kamiyatakeshi thefirstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT johtakashi thefirstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT tanidasatoshi firstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT mizoshitatsutomu firstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT ozekikeiji firstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT tsukamotohironobu firstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT moriyoshinori firstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT kubotaeiji firstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT kataokahiromi firstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT kamiyatakeshi firstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis
AT johtakashi firstcaseofbiologicaltherapydiscontinuationafteracompleteremissioninducedbymaintenancetherapywithadalimumabforrefractoryulcerativecolitis

Ejemplares similares